{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:39Z","timestamp":1792268619058,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jpba.2020.113634","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:27:18Z","timestamp":1600306038000},"page":"113634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma"],"prefix":"10.1016","volume":"191","author":[{"given":"Mengqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Shan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113634_bib0005","first-page":"151","article-title":"Phosphodiesterase-5inhibitors in management of pulmonary hypertension: safety, tolerability,and efficacy","volume":"2","author":"Buckley","year":"2010","journal-title":"Drug Healthc. Patient Saf."},{"key":"10.1016\/j.jpba.2020.113634_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms ofdisease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jpba.2020.113634_bib0015","first-page":"20","article-title":"Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study","volume":"14","author":"Ozpelit","year":"2017","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/j.jpba.2020.113634_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3904\/kjim.2001.16.2.75","article-title":"Survival and prognostic factors in patients with primary pulmonary hypertension","volume":"16","author":"Chun","year":"2001","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.jpba.2020.113634_bib0025","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpba.2020.113634_bib0030","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1021\/jm030056e","article-title":"The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1H-imidazo[1\u2018,5\u2018:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues","volume":"46","author":"Daugan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2020.113634_bib0035","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/jm0300577","article-title":"The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1\u2018,2\u2018:1,6]pyrido[3,4-b]indole-1,4-dione analogues","volume":"46","author":"Daugan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2020.113634_bib0040","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Pulmonary Arterial, H.; Response to Tadalafil Study, G. Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jpba.2020.113634_bib0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1569-9056(02)80240-8","article-title":"Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families","volume":"1","author":"Gbekor","year":"2002","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jpba.2020.113634_bib0050","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1464-410X.2008.08267.x","article-title":"Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies","volume":"103","author":"Mirone","year":"2009","journal-title":"BJU Int."},{"key":"10.1016\/j.jpba.2020.113634_bib0055","doi-asserted-by":"crossref","first-page":"I14","DOI":"10.1002\/clc.4960271305","article-title":"Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles","volume":"27","author":"Seftel","year":"2004","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.jpba.2020.113634_bib0060","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.bmcl.2009.03.125","article-title":"2-Phenylquinazolin-4 (3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6","volume":"19","author":"Duan","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jpba.2020.113634_bib0065","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1021\/jm301159y","article-title":"Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5","volume":"55","author":"Wang","year":"2012","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jpba.2020.113634_bib0070","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.jmedchem.9b00123","article-title":"Pharmacokinetics-driven optimization of 4(3 H)-Pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2020.113634_bib0075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jpba.2019.05.001","article-title":"Characterization of TPN171 metabolism in humans viaultra-performance liquid chromatography\/quadrupole time-of-flightmass spectrometry","volume":"172","author":"Pan","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113634_bib0080","author":"European Medicines Agency","year":"2012","journal-title":"Guideline on bioanalytical method validation"},{"key":"10.1016\/j.jpba.2020.113634_bib0085","series-title":"Food and Drug Administration, Bioanalytical Method Validation Guidance for Industry","author":"U.S. Department of Health and Human Services","year":"2018"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852031520X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852031520X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:11:49Z","timestamp":1760001109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852031520X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":17,"alternative-id":["S073170852031520X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113634","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113634"}}